• A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer

  NCT02888366

  CompletedObservationalUpdated Oct 29, 2018
• Breath Test for Early Detection of Lung Cancer

  NCT00639067

  CompletedObservationalUpdated May 16, 2014
• Identifying Patterns in the Breath of Individuals With Breast Cancer

  NCT06512350

  RecruitingObservationalUpdated Apr 22, 2026
• Breath Gas Analysis for the Diagnosis of Breast Cancer

  NCT01105468

  TerminatedObservationalUpdated Jan 14, 2013
• Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy

  NCT04556435

  TerminatedObservationalUpdated Nov 18, 2023
• Breath Research Narrow Validation for Gastrointestinal Cancer Detection

  NCT07714538

  Not yet recruitingObservationalUpdated Jul 23, 2026

ClinicalTrials.gov ID

NCT04755829

Lead Sponsor

Menssana Research, Inc.INDUSTRY

Overall Status

Unknown status

Study Type

Observational

Enrollment

1,000Estimated

Last Update Posted

Feb 16, 2021Actual

Start Date

Mar 2021Estimated

Primary Completion Date

Mar 2023Estimated

Completion Date

Mar 2023Estimated

Official Title

Breath Test to Predict Breast Cancer and Outcome of Mammography

Brief Summary

To validate a breath test that predicts risk of breast cancer and an abnormal mammogram.

Detailed Description

We will determine the accuracy of volatile organic compounds (VOCs) in the breath as predictors of risk of breast cancer and an abnormal mammogram. Breath samples will be collected using an ultra-clean collection bag and analyzed with gas chromatography surface acoustic wave detection (GC SAW)

The study will be performed in two phases:

Phase 1: Model-building phase (cross-sectional study): Breath VOCs will be employed to construct multivariate algorithms that distinguish between normal women and those with breast cancer and abnormal screening mammograms.

Phase 2: Model-testing phase (cross-sectional study): The predictive accuracy of these algorithms will be tested to predict outcomes in normal women and those with breast cancer and abnormal screening mammograms.

• Breast Cancer
• Abnormal Mammogram, Unspecified

• BreathX test for breath VOCs

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

No data available

Eligibility Criteria

Group 1: Normal screening mammogram

Inclusion Criteria:

1. Female aged 18 years or older
2. Understands the study, and is willing to give written informed consent to participate
3. If a screening mammogram was performed during the preceding six month period, then the results were reported as normal (BIRADS 1 or 2)
4. If a screening mammogram was not performed during the preceding six month period, then approves collection of the results of a screening mammogram if and when it is performed subsequently*.
5. Approves collection of relevant additional data for clinical research record if and when these data become available, including results of imaging studies, breast biopsy, and other relevant biomarker data e.g. status of BRCA1, BRCA2, HER2 and receptors (ER+ or ER-) and progesterone (PgR+ or PgR-) * If a subsequent screening mammogram is reported as abnormal, the subject will be transferred to Group 2 for analysis of data.

Exclusion Criteria:

1. Previous history of an abnormal mammogram, breast disease, or breast biopsy
2. Previous history of cancer of any site, with the exception of basal cell carcinoma of skin
3. Concurrent serious or potentially life-threatening disease (e.g. severe cardiac or infectious disease)
4. Concurrent acute pulmonary disease (e.g. influenza, influenza-like illness, acute asthma, or pneumonitis).
5. General anesthesia during the 10-day period prior to breath collection.

Group 2: Abnormal screening mammogram

Inclusion Criteria:

Female aged 18 years or older

1. Understands the study, and is willing to give written informed consent to participate
2. Abnormal screening mammogram during preceding six months (BIRADS 3-6)
3. Approves collection of relevant additional data for clinical research record if and when it becomes available, including results of imaging studies, biopsy results, and other relevant biomarker data e.g. status of BRCA1, BRCA2, HER2 and receptors (ER+ or ER-) and progesterone (PgR+ or PgR-)

Exclusion criteria:

1. Previous history of cancer of any site, with the exception of basal cell carcinoma of skin
2. Previous history of breast biopsy
3. Concurrent serious or potentially life-threatening disease (e.g. severe cardiac or infectious disease)
4. Concurrent acute pulmonary disease (e.g. influenza, influenza-like illness, acute asthma, or pneumonitis).
5. General anesthesia during the 10-day period prior to breath collection. -

Observational Model

Other

Time Perspective

Cross-Sectional

Lead Sponsor

Menssana Research, Inc.INDUSTRY

Collaborators

Mount Vernon Cancer CentreUNKNOWN

Zuyderland Medical CentreOTHER

University of Erlangen-NürnbergOTHER

mbi.lobbes@gmail.com